Oruka Therapeutics Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Public

  • Employees
  • 68

Employees

  • Stock Symbol
  • ORKA

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $95.81
  • (As of Friday Closing)

Oruka Therapeutics General Information

Description

Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.

Contact Information

Website
www.orukatx.com
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • 203 Crescent Street Building 21
  • Suite 203
  • Waltham, MA 02453
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Corporate Office
  • 203 Crescent Street Building 21
  • Suite 203
  • Waltham, MA 02453
  • United States

Oruka Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Oruka Therapeutics Stock Performance

As of 20-Nov-2026, Oruka Therapeutics’s stock price is $95.81. Its current market cap is $6.5B with 67.8M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$95.81 $97.45 $25.23 - $115.52 $6.5B 67.8M 965K -$2.12

Oruka Therapeutics Financials Summary

As of 30-Sep-2026, Oruka Therapeutics has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022
EV 4,646,519 1,122,972
Revenue 0 0
EBITDA (182,929) (121,980)
Net Income (152,574) (105,433)
Total Assets 1,231,026 488,617 37,900 43,100
Total Debt 2,932 1,932 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Oruka Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Oruka Therapeutics‘s full profile, request access.

Request a free trial

Oruka Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Oruka Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Oruka Therapeutics‘s full profile, request access.

Request a free trial

Oruka Therapeutics Acquisitions (1)

Oruka Therapeutics’s most recent deal was a Merger/Acquisition with Arca Biopharma. The deal was made on 29-Aug-2024.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Arca Biopharma 29-Aug-2024 Merger/Acquisition Drug Discovery
To view Oruka Therapeutics’s complete acquisitions history, request access »

Oruka Therapeutics ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view Oruka Therapeutics’s complete esg history, request access »

Oruka Therapeutics FAQs

  • When was Oruka Therapeutics founded?

    Oruka Therapeutics was founded in 2015.

  • Where is Oruka Therapeutics headquartered?

    Oruka Therapeutics is headquartered in Waltham, MA.

  • What is the size of Oruka Therapeutics?

    Oruka Therapeutics has 68 total employees.

  • What industry is Oruka Therapeutics in?

    Oruka Therapeutics’s primary industry is Drug Discovery.

  • Is Oruka Therapeutics a private or public company?

    Oruka Therapeutics is a Public company.

  • What is Oruka Therapeutics’s stock symbol?

    The ticker symbol for Oruka Therapeutics is ORKA.

  • What is the current stock price of Oruka Therapeutics?

    As of 20-Nov-2026 the stock price of Oruka Therapeutics is $95.81.

  • What is the current market cap of Oruka Therapeutics?

    The current market capitalization of Oruka Therapeutics is $6.5B.

  • What is Oruka Therapeutics’s annual earnings per share (EPS)?

    Oruka Therapeutics’s EPS for 12 months was -$2.12.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process